North Brunswick-based LinusBio announced that ClearStrand-ASD, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. The Japanese launch builds on ClearStrand-ASD’s successful rollout across the United States, where it is now available in 49 states.
This milestone marks LinusBio’s inaugural international expansion and represents a significant step in the company’s mission to enable earlier identification of autism spectrum disorder (ASD) globally.
ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, noninvasive approach provides health care providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development.
“Today marks a transformational moment in our mission to make early autism screening accessible worldwide,” said Dr. Manish Arora, founder and CEO of LinusBio. “Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated health care infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before.”
LinusBio’s expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio’s scaling efforts globally.
